Kornimate/medical-research-clean huggingface dataset:
apnea and insomnia relief study

Conditions: Sleep Apnea Syndromes; Insomnia Disorder; Stress Disorders, Post-Traumatic

Summary: the purpose of this study is to determine whether a behavioral sleep treatment improves functioning and sleep in veterans with posttraumatic stress disorder (ptsd).

this study is a randomized controlled trial of a behavioral sleep treatment to improve functioning and sleep in veterans with ptsd, sleep apnea, and insomnia. the treatment is delivered via telehealth (video to home). the primary outcome for this study is quality of life. other outcomes include sleep-related functioning, ptsd symptom severity, insomnia symptom severity, and cpap adherence. participants will also provide treatment feedback to aid in assessment of treatment feasibility and acceptability.

Eligibility criteria:
inclusion criteria: * veterans diagnosed with sleep apnea with apnea hypopnea index of at least 5 via sleep study and recommended for pap therapy * meet dsm-5 criteria for posttraumatic stress disorder or subthreshold posttraumatic stress disorder * meet dsm-5 criteria for insomnia disorder * willing to attend all treatment and assessment appointments * english literacy and cognition sufficient to participate in treatment and assessment exclusion criteria: * psychosis or manic episode in last 5 years * moderate or severe substance use disorder in past 6 months * started or ended psychotherapy for a sleep disorder or mental health diagnosis within the last 1 month or plans to discontinue this treatment during the trial * started or ended an antidepressant, anxiolytic, or sleep medication with the last 1 month or plans to discontinue this treatment during the trial * prominent suicidal or homicidal ideation requiring alternative treatment for patient safety * untreated sleep disorders that may interfere with successful treatment (up to discretion of principal investigator) * having travel of personal plans that would disrupt regular treatment engagement (up to discretion of principal investigator) * working night shifts or rotating shifts that include night shifts * lack of stable housing * pregnancy

Keywords: sleep apnea syndromes sleep apnea, central sleep apnea, obstructive sleep initiation and maintenance disorders insomnia insomnia disorder stress disorders, post-traumatic ptsd veterans
mhealth for prevention of childhood obesity in mexico

Conditions: Overweight and Obesity

Summary: background: the sending of text messages (short messaging service, sms) has been proven as an effective strategy in behavior change. in mexico, the strategy of comprehensive care for the nutrition (esian for its acronym in spanish ) focuses on improving access to information for the main caregivers of child beneficiaries on the practice of infant feeding and healthy physical activity. objective: to assess whether the mhealth (or mobile health) strategy or the sending of sms has an effect on knowledge, attitudes, intentionality, perceived control and practices to prevent childhood malnutrition in a population living in poverty. design: randomized effectiveness trial by conglomerates. participants: 400 primary caregivers of children \<59 months and health personnel working in the health units included in the study. control group: healthy child care in standard health units plus exposure to esian. intervention group: in addition to the control group, the sms are sent through a cell pone through the rapidpro platform on practices related to prevention of child malnutrition (in primary caregivers) and the reinforcement of counseling for the prevention of infant malnutrition (with health personnel). randomization: the first level health units were stratified by state (morelos or yucatan); rural and urban area and affiliation institution (secretary of health or mexican institute of social security); and randomized to be assigned to the control or intervention group; 400 primary caregivers of children \<59 months in total will be included for the study. main measures of interest: state of nutrition and knowledge, attitudes or practices on breastfeeding, physical activity, adoption and preparation of healthy foods and beverages in primary caregivers of children\<5 years old; and advice on the key messages of esian by health providers.

rapidpro is a tecnological platform of programming of short messaging service (sms) for cell phone. morelos is the name of one of the central states of mexico yucatan is the name of one of the south states of mexico

Eligibility criteria:
inclusion criteria: * primary caregivers whose beneficiaries children are cared in the health units selected for the study and who have a cell pone in home * health personnel who provides services to prospera population in the health units selected for the study and that have a cell pone * primary caregiver, must care for at least one child under 60 months users of the health units selected for the study exclusion criteria: * primary caregivers and health personnel who do not have a cell pone or who do not have connectivity in their communities * health personnel, who have been in office for a least 3 months

Keywords: randomised controlled trial text messaging infant feeding practice health unit bmi mobile phone prevention
a rollover protocol to allow for continued access to the lsd1 inhibitor seclidemstat (sp-2577)

Conditions: Ewing Sarcoma; Myxoid Liposarcoma; Desmoplastic Small Round Cell Tumor; Extraskeletal Myxoid Chondrosarcoma; Angiomatoid Fibrous Histiocytoma; Clear Cell Sarcoma; Myoepithelial Tumor; Low Grade Fibromyxoid Sarcoma; Sclerosing Epithelioid Fibrosarcoma

Summary: this rollover protocol allows continued access to seclidemstat (sp-2577) for patients who are still receiving clinical benefit on completed or closed salarius sponsored studies.

the population for the rollover study should be consistent with the population defined in the parent study. the primary eligibility criteria for a patient to enter the rollover protocol is the participation and completion of a salarius sponsored study with seclidemstat. safety data and an evaluation of anti-tumor activity will be collected. patients who have completed a prior study with seclidemstat and who are assessed by the investigator to continue to benefit from ongoing treatment will be eligible.

Eligibility criteria:
inclusion criteria: 1. patient is currently enrolled in a salarius-sponsored study that is approved to enroll into this rollover study, and are receiving seclidemstat as monotherapy or in combination with other study treatment per the parent protocol (i.e. topotecan and cyclophosphamide). the maximum time between discontinuing the parent protocol and starting this rollover protocol is 14 days. 2. patient is currently benefiting from the treatment with seclidemstat monotherapy or combination treatment, as determined by the investigator 3. patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements 4. willingness and ability to comply with scheduled visits, treatment plans and any other study procedures 5. ability to understand and the willingness to sign a written informed consent document. 6. women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of seclidemstat administration. exclusion criteria: 1. patient has been permanently discontinued from study treatment in the parent study due to any reason, except for the purpose of entering this open label rollover study. 2. pregnant and breastfeeding women are excluded from this study. the effects of seclidemstat on the developing human fetus have the potential for teratogenic or abortifacient effects. there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with seclidemstat. 3. patient is receiving prohibited concomitant therapy as described in section 5.4.2 of the rollover protocol, or therapy not allowed in the parent protocol.
effect of hcp on nutrition, physical activity and body mass index

Conditions: Obesity; Adolescent Obesity

Summary: the goal of this clinical trial is to test effectiveness of "the healthy choices program, in adolescents. the main question\[s\] it aims to answer are: 1. effectiveness of healthy choices on body mass index 2. effectiveness of healthy choices on health attitude, nutrition and physical activity knowledge 3. effectiveness of healthy choices on fruit,vegetable, water consumption

in our study, a quasi-experimental design with a pre-test and post-test control group was used. this study was carried out between may 2022 and january 2023. 150 adolescents in the 5th, 6th and 7th grades of two secondary schools in istanbul were included in the study. one of the schools was designated as the intervention group (n=75) and the other as the control group (n=75). six sessions of training were given to the intervention group. data were collected using the descriptive characteristics form, healthy habits questionnaire, adolescent attitude scale, adolescent physical activity knowledge scale, adolescent nutrition knowledge scale and physical activity questionnaire. chi-square test, t test, mann-whitney u test, wilcoxon test were used to analyze the data.

Eligibility criteria:
inclusion criteria: * male and female adolescents in 6th, 7th and 8th grades * adolescents without mental disabilities * families and adolescents who agree to participate in the study exclusion criteria: * families and adolescents who did not agree to participate in the study were not included in the study.

Keywords: school nursing healthy choices nutrition physical activity
discoloration of carious primary teeth after application of silver diamine fluoride versus sodium fluoride varnish

Conditions: Dental Caries in Children

Summary: to assess discoloration of carious primary teeth after application of silver diamine fluoride versus sodium fluoride varnish.

the american academy of pediatric dentistry's (aapd) guidelines (2017) stated that silver diamine fluoride (sdf) is a brush-on liquid that arrest 87.7% of dental caries lesions. the success rate is similar for restorations placed under ga. one of the most exciting aspects of sdf is the 67±4% decrease in new lesions on untreated surfaces, achieved simply by treating active lesions .this is not the same as incidence of any new lesions (elaborated above for treatment under ga), however the relation warrants further investigation. benefit to the patient * no pain and infection. * enhance child cooperation. * enhance better patient compliance. * decrease cost of dental treatment and may eliminate the need for general anesthesia. benefit to the dentist * develop an effective fast easy method to arrest the caries by using sdf. * ease of dental treatment. * better cooperation with the child. * the procedure is simple. * inexpensive and non-invasive. * it does not require expensive equipment or support infrastructure, such as pipe water or electricity. benefit to the population * reduce the harmful impact of oral health problems in preschool children from low income families. * sdf can be considered a user-friendly material for use in dental clinics as well as remote areas, schools or deprived communities. children aged 2-5 years can benefit from the use of sdf, an easy anticaries treatment. furthermore, children in this age group may benefit from delayed dental treatment and overall caries arrest, thus reducing potential pain and infection, expensive future emergency room visits, the need for general anesthesia or traumatic dental experiences on uncooperative children.

Eligibility criteria:
inclusion criteria: 1. children with carious primary teeth before eruption of permanent teeth 2. high caries risk patients with anterior or posterior carious lesions 3. uncooperative children without access to or with difficulty accessing dental care. exclusion criteria: 1. children with spontaneous or elicited pain from caries 2. tooth mobility 3. signs of pulpal infection 4. severe medical conditions that would not allow management in the clinic
bimodal analgesia as form of pain control post long bone fracture

Conditions: Tibia Fracture; Femur Fracture; Humerus Fracture

Summary: the purpose of this prospective randomized study is to evaluate the risks and benefits of using bimodal analgesia, (i.e. narcotics and nsaids) vs narcotics alone post long bone fracture.

this will be a prospective, randomized, control trial looking at the benefit of bimodal analgesia in the treatment of long bone fractures. the traditional pain control regimen following fracture fixation typically involves a course of narcotics on an as-needed basis for pain relief. recent data has shown that adding nsaids to the pain regimen as part of a bimodal approach to pain control, improves the efficacy of pain management and reduces narcotic use. laboratory research on nsaids as it pertains to bone healing, however, has shown in animal models that there may be a positive association between nsaids and non-union rates. in other words, nsaids may prevent or delay bone healing. these results, however, have not been tested prospectively in humans. the purpose of this study is to look at the combination of nsaids and narcotics post long bone fracture and monitor the effects on narcotic use and healing rates to ultimately and conclusively establish the risk or benefit of nsaids after long bone fracture.

Eligibility criteria:
inclusion criteria: * skeletally mature patients over the age of 18 years * fracture of tibia, femur, or humerus. exclusion criteria: * open fractures grade iii * open fractures with suspected compartment syndrome * history of prior fracture in particular limb. * concurrent usage of steroid drugs, and immunosuppressants. * prior or current history of gi bleeding.

Keywords: fracture tibia femur humerus narcotics bimodal analgesia long-bone nsaids
the comparative study on the efficacy and safety of single acupoint and matching acupoints

Conditions: Electro-acupuncture; Chemotherapy-induced Nausea and Vomiting

Summary: the purpose of this study is to clarify whether the matching acupoints are more effective than a single point by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting.


Eligibility criteria:
inclusion criteria: 1. be diagnosed as cancer and need to accept chemotherapy 2. the score of karnofsky ≥70 3. patients of either gender and age 18 years to 80 years 4. patients receiving chemotherapy both outpatients and inpatients 5. patients receiving chemotherapy regime with high risk of causing vomiting: cisplatin ≥60 mg/m2, or joint chemotherapy regime of anthracyclines (adriamycin≥ 40 mg/ m2 or epirubicin≥60 mg/m2), dacarbazine or carboplatin（area under the curve greater than 5mg/ml/min） 6. life expectancy \> 6 months exclusion criteria: 1. to receive radiotherapy and chemotherapy 2. gastrointestinal tumors 3. patients with serious liver disease or abnormal hepatorenal function (aspartate aminotransferase, alanine aminotransferase , and total bilirubin are 3 times more than normal, blood urea nitrogen and cr are 2 times more than normal) 4. presence of cardiac pacemaker 5. inflammatory skin reaction 6. nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolytic disturbances) 7. patients unable to provide self-care or communication 8. nausea and/or vomiting resulting from mechanical risk factors (i.e.,intestinal obstruction) 9. patients with brain metastases or symptoms of intracranial hypertension 10. nausea and/or vomiting resulting from other diseases(i.e.,sympathetic cervical dispositions, meniere's syndrome) 11. women in pregnant and lactating period 12. refusal to sign informed consent, rejection of randomization into intervention groups.
registry of right-to-left shunt detection by contrast-enhanced transcranial doppler in chinese population

Conditions: Right-to-left Shunt; Migraine; Cerebral Infarction

Summary: the purpose of the study is to evaluate the prevalence and extent of right-to-left shunt (rls) in chinese migraineurs, and the morbidity of silent cerebral infarction in migraineurs.

this is a prospective multicenter study of chinese population. participants (normal individuals without migraine and migraineurs) are included after standardized diagnostic procedures (tcd and c-tcd). for migraineurs with large rls further examinations (c-tte and brain mri) are required. up to 10 study sites nationwide will be needed to recruit the planned participant population during a 1-year period. the information of each participants will be registered, including basic facts, the longitudinal headache history, frequency, location, quality, intensity, duration, accompanied symptoms, precipitating and exacerbating factors, with or without aura, midas and hit-6 questionnaire.

Eligibility criteria:
inclusion criteria: * for group 1: normal healthy individual without migraine. * for group 2: clinical history of migraine diagnosed by a neurologist according to the international classification of headache disorders. exclusion criteria: * subjects with stenotic intracranial or extracranial arteries or intracranial abnormalities diagnosed with tcd.

Keywords: right-to-left shunt contrast-enhanced transcranial doppler migraine silent cerebral infarction
clinical-immunological features of dner ataxia

Conditions: DNER Ataxia

Summary: using a retrospective cohort of 34 patients with dner ataxia, we will characterize clinical presentation, tumor associations, and outcomes.


Eligibility criteria:
inclusion criteria: * patient \> 18 years old * patient with neurological disorder * patient with dner antibodies in sera or csf exclusion criteria: * - no available clinical data * patient without dner antibodies or neurological disorder

Keywords: dner antibodies autoimmune cerebellar ataxia hodgkin lymphoma
a study exploring the pk/pd relationship of qrl-101 in adults with als

Conditions: Amyotrophic Lateral Sclerosis

Summary: this phase 1 randomized, placebo-controlled, double-blind study will evaluate the pk/pd relationship of single doses of qrl-101 in 12 als participants. the study will also assess safety and tolerability in participants receiving either qrl-101 or placebo.

this is a randomized, placebo-controlled, double-blind, single-dose, single-site, phase 1 study to explore the pharmacokinetics (pk) and pharmacodynamics (pd) of single doses of qrl-101 in participants with als. in addition, the safety and tolerability of qrl-101 will be evaluated. single doses of qrl-101 or placebo will be administered as an oral liquid to approximately 12 participants with als. the study will explore the pk, pd, and pk/pd relationship among three dose levels of qrl-101 and placebo. the randomization will be 1:1:1:1 for the four study groups and will be conducted in 3 blocks (cohorts) of 4, where participants will be randomized 3:1 (qrl-101:placebo) for increasing dose levels of qrl-101.

Eligibility criteria:
inclusion criteria 1. age 18 to 80 years of age inclusive at the time of signing the informed consent. 2. diagnosis of als, by either gold coast criteria or el escorial criteria (possible, probable laboratory supported, probable, or definite) 3. clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment. 4. body mass index of 18 to 32 kg/m2 (inclusive). 5. willing and able to practice effective contraception. exclusion criteria 1. currently enrolled in any other clinical trial involving a study drug, off-label drug or device use, or any other type of medical research judged not scientifically or medically compatible with this study. 2. history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation. 3. off-label use of drugs or devices that are being used or investigated as disease-modifying therapies in als 4. participated in another clinical study within 30 days, or 5 half-lives of the previous investigational product, whichever is greater, prior to the planned randomization date. 5. taking any prescription or nonprescription medicines that are cytochrome p450 3a4 inducers, inhibitors, or substrates within 30 days or 5 half-lives, whichever is greater, prior to the planned randomization date
a prospective, open, non-controlled clinical investigation to evaluate a new negative pressure wound therapy (npwt) system to be used in the treatment of acute non-infected wounds and post surgical infected wounds

Conditions: Acute Non Infected Wounds; Non Infected Post Surgical Wounds

Summary: the investigation is designed as a prospective, open, non-controlled clinical investigation.

wounds to be treated under this protocol should be acute non-infected wounds or post surgical infected wounds in hospitalized subjects. one ulcer per subject will be treated for a maximum duration of 3 weeks. all subjects will receive continuous negative pressure treatment with the new npwt system with a pressure level of -120 mmhg or according to clinicians' instruction based on the indication. 10-15 subjects at two sites will be enrolled provided that they fulfil all the inclusion criteria and none of the exclusion criteria and who have signed and dated a written informed consent. the subjects will be consecutively allocated to a specific subject identification code. the primary variable wound healing and granulation tissue formation will be assessed by digital planimeter, digital photography and visual estimation. subject pain will be measured by using the visual analogue scale, vas. subject and investigator convenience will be assessed by convenience surveys. diagnosis and treatment of wound infections according to clinical routine.

Eligibility criteria:
inclusion criteria: 1. acute non infected wound or infected post surgical wound suitable for negative pressure wound therapy according to the investigator's judgment 2. 3 cm2 ≤ wound size ≤ 300 cm2 3. male or female ≥18 years 4. signed informed consent form exclusion criteria: 1. need for frequent dressing changes, i.e.\<48 hours between the changes 2. dry wounds 3. malignancy in the wound and/or wound margin 4. untreated osteomyelitis 5. untreated infection waiting for other intervention 6. unexplored fistulas 7. \> 10% necrotic tissue with eschar present after debridement 8. high risk for bleeding complications (including subject treated with anticoagulants that are associated with high risk for bleeding complications) 9. exposed blood vessels, organs or nerves 10. current or within 3 months treatment with chemotherapy or irradiation 11. known hypersensitivity to the dressing material 12. expected technically impossible to seal the film to achieve a vacuum treatment 13. expected non compliance with the clinical investigation plan 14. pregnancy 15. subjects previously included in this investigation 16. subjects included in other ongoing clinical investigation at present or during the past 30 days 17. target ulcer previously not successfully treated with npwt within 48 hours from npwt start 18. subject unable to understand written patient information due to medical condition